Federal Health Grants

This funding opportunity provides financial support to a variety of organizations to strengthen public health systems in Cote d'Ivoire, focusing on improving disease detection, response, and prevention capabilities.

This grant provides access to essential resources and expertise for researchers developing gene-based therapies for ultra-rare neurological diseases, helping them advance their projects toward regulatory approval without direct funding.

The "USAID Multi Sector Nutrition in the Democratic Republic of Congo" grant aims to improve nutrition outcomes, particularly for women of reproductive age and children under five, in rural and hard-to-reach communities in select provinces, by strengthening local capacity to coordinate and implement multi-sectoral initiatives that promote availability of diverse, nutritious foods, positive social and cultural norms, and integrated nutrition services.

This grant provides funding for researchers and organizations to develop innovative medical countermeasures for treating acute chemical exposures resulting from terrorist attacks or accidental releases, enhancing national preparedness for chemical emergencies.

This grant provides funding to U.S.-based educational institutions, nonprofits, and community organizations to improve mental health and substance use treatment practices in outpatient settings, particularly for underserved populations.

This funding opportunity supports innovative research on the role of defective HIV proviruses in viral persistence and their impact on treatment strategies, targeting a wide range of eligible applicants including universities, nonprofits, and international organizations.

This grant provides funding for research projects that improve mental health services and outcomes for young people experiencing early stages of psychosis by promoting data-driven care and collaboration among specialized treatment programs across the United States.

This funding opportunity provides financial support to federally recognized American Indian and Alaska Native tribes and organizations to implement community-driven suicide prevention strategies for youth and young adults.

This funding opportunity provides financial support for organizations to archive and document child health and human development data sets, facilitating their accessibility for secondary analysis by researchers.

The USAID THRIVE activity aims to contribute to achieving sustained epidemic control by improving the health and wellbeing of children living with HIV and reducing the risk of HIV infection among vulnerable children, adolescents, and caregivers. The activity will provide a suite of comprehensive services to build resilience and mitigate the multiple, layered vulnerabilities faced by these sub-populations. The target population for THRIVE activity is children and adolescents living with HIV (CALHIV), children whose caregivers are living with HIV (CPLHIV), HIV exposed infants (HEI), children of key populations (CKP), survivors of sexual violence against children (SVAC), and high-risk adolescent boys and girls, including out of school children.

This funding opportunity provides financial support for researchers and organizations developing innovative long-acting treatments for HIV and related co-infections, aiming to improve patient adherence and health outcomes.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development and validation of reagents/tools to support research to characterize cellular and molecular constituents of the bat immune system and for the study of protective innate and adaptive immune mechanisms in bats. The Research Resource Program established by this NOFO will participate within a collaborative research network to advance understanding of the bat immune response. This NOFO will support the establishment and operation of a Bat Immunology Research Resource Program for the development and validation of reagents/tools for use in immunological studies using the bat model system. The recipient will participate in the Bat Immunology Network, which will consist of the Research Resource Program, the research projects supported by RFA-AI-23-068, and possible other participants as determined by NIAID. The Research Resource Program will conduct reagent/tool development and validation using appropriate systems, which includes testing against multiple bat species. While other members of the Bat Immunology Network may assist in validation efforts, reagent/tool validation is the responsibility of the Research Resource Program. Reagents/tools developed by the Research Resource Program will be provided to the research projects of the Bat Immunology Network. Reagents/tools will be made available to the broader research community through technology transfer arrangements, deposition to nonprofit repositories, and/or timely transfer to industry for commercialization. Areas of high priority include, but are not limited to, the development and validation of the following: Soluble immune molecules (e.g., cytokines, chemokines) for use in tissue culture or in vivo animal studies Antibodies or other probes/detection markers for use in cellular phenotyping, functional studies and/or immunoassays

This funding opportunity provides financial support to a wide range of organizations, including universities, nonprofits, and government entities, to enhance research and programs aimed at controlling and eliminating parasitic and neglected tropical diseases that threaten public health in the U.S. and globally.

This funding opportunity provides financial support to community organizations that deliver tailored suicide prevention services for veterans and certain active-duty service members at risk of suicide, focusing on their unique needs and social determinants of health.

This funding opportunity supports innovative research aimed at developing new strategies for curing HIV at the start of antiretroviral therapy, targeting researchers and institutions focused on reducing the HIV reservoir and improving immune responses.

This funding opportunity supports research projects that analyze existing national data to improve healthcare access and outcomes for children and adolescents with autism and developmental disabilities, particularly in underserved populations.

This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Transition to the R33 phase is not guaranteed for all grants awarded under this FOA. Continuation from the R21 phase to the R33 phase will be determined by AHRQ staff based on progress achieved in the R21 phase and factors such as program priorities and availability of funds.

The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research.The purpose of this Funding Opportunity Announcement (FOA) is to support epidemiologic studies that utilize creative and innovative approaches to studying vision diseases and disorders with high public impact and whose findings will inform prevention and treatment strategies as well as basic sciences research. Background: Clinical vision research projects, including epidemiologic studies, are part of NEI’s core strategy for improving visual health and decreasing visual impairment in populations through research on the burden of disease, its causes, diagnosis, prevention, treatment and rehabilitation. Projects should focus on NEI’s mission to protect and improve visual health including, but not limited to: Determining the burden of eye diseases and their visual outcomes in a changing population, particularly disparities in the burden and the influences of sociocultural, environmental, economic, and demographic factors. Improving early diagnosis of ocular diseases and their underlying processes through new screening and detection strategies. Determining risk factors for ocular diseases. Identifying and assessing strategies that will overcome barriers to eye care and convert evidence-based findings into improved patient and population outcomes. Studying the interplay of factors that exacerbate or mitigate risk for eye diseases. The NEI encourages applications to support ocular epidemiologic research. These projects are supported under the cooperative agreement mechanism. Applicants are strongly encouraged to contact Scientific/Research staff as plans for an application are being developed (see Section VII, Agency Contacts), preferably no later than 12 weeks prior to the anticipated application submission date.

Despite huge advances in the development of novel medical therapies, Americans still live with poor health outcomes and suffer from the ill-effects of disease. Current medical research and the medical delivery system in the United States focus primarily on the reactive treatment of illnesses, despite the fact that many diseases or their ill-effects are preventable.The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Specifically, PHO hypothesizes that 1) population-level improvements in access to and uptake of disease prevention and wellness-promoting behaviors and 2) development of novel early-detection methods and prophylactic interventions could drastically improve the health of American throughout their lives, and 3) that system level innovations are required for delivery of proactive health effectively. Specific PHO interest areas include:Novel prevention, detection and prophylactic treatment methods for disease: Novel and scalable methods for early detection of disease and illness including the use of low/no-cost sensing modalities. Prophylactic approaches to prevention of diseases and harmful disease outcomes. Methods for continuous and widespread sensing of health state and early disease indicators that can be deployed at population-scale.Population-level approaches to increase the adoption of prevention and wellness behaviors: Early indicators of disease and pre-disease states and measures associated with proactive health outcomes that are both inexpensive and effective. Low-cost, high-uptake mental health resiliency and mindfulness building methods for individuals. Methods to inform and educate individuals about healthy behaviors including lifestyle and preventative medical measures. Methods that incentivize individuals to adopt and maintain healthy behaviors. Novel approaches to increasing individual healthspan and independence even in the absence of disease.System innovation for the delivery of proactive health outcomes: Novel, robust and predictive surrogates for long-term health outcomes with associated epidemiological models. Valuation models for long-term treatment effects for vaccination, screening and other public health interventions. New funding and delivery models for preventative intervention.Other high-quality submissions that propose revolutionary technologies that meet the goals of PHO will be considered even if they do not address the topics listed above.Proposals are expected to use innovative approaches to enable revolutionary advances in medicine and healthcare, and the science and technology underlying these areas. While approaches that are disease agnostic are encouraged, ARPA-H welcomes proposals that bring radically new insights to address specific diseases including, but not limited to, cancer, diabetes, neurological diseases, pediatric and maternal/fetal health, infectious diseases, and cardiovascular disease.Specifically excluded are proposals that represent an evolutionary or incremental advance in the current state of the art or technology that has reached the clinical trial stage. An example of this type of proposal might include the request to fund clinical trials of an otherwise developed product. Additionally, proposals directed towards policy advocacy, traditional education and training, or center coordination, formation, or development, and construction of physical infrastructure are outside the scope of the ARPA-H mission.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.